

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: Sativa Wellness Group Inc. (the "Issuer").

Trading Symbol: SWEL

Number of Outstanding Listed Securities: 364,615,913

Date: June 30, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

*The Company announced that following its collaboration with King's College London, investigating the potential therapeutic use of cannabinoids for the treatment of respiratory diseases, a research paper including the results of part of this research has been published.*

---

### **FORM 7 – MONTHLY PROGRESS REPORT**

October 2020

Page 1

*The primary purpose of this study was to investigate the anti-inflammatory effects of two of the non-psychoactive cannabinoids, cannabidiol (CBD) and cannabigerol (CBG) alone and in combination, in a model of pulmonary inflammation. The results of the work suggest that the cannabinoids CBD and CBG in combination have significant anti-inflammatory activity in the lung.*

*The work undertaken builds on previous research that suggests cannabinoids are promising potential treatments for inflammatory diseases. Another important part of the research identified that the formulation for administering cannabinoids is critically important to obtain efficacy and highlights the importance of choosing an appropriate formulation to obtain optimal benefit from administering cannabinoids.*

2. Provide a general overview and discussion of the activities of management.

*None to report*

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

*The Company announced that opened its 40th clinic, and that it was also expected to list shortly through Patient Access. Sativa has also introduced blood testing for COVID-19 immune response through some of the clinics. The listing approval on Patient Access, a National Health Service numbering 12million registered users, is expected to boost customer numbers even further.*

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

*None to report*

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

*None to report*

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

*None to report*

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable

---

## FORM 7 – MONTHLY PROGRESS REPORT

October 2020  
Page 2

together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

*None to Report.*

8. Describe the acquisition of new customers or loss of customers.

*None to Report.*

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

*None to Report.*

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

*None to Report.*

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

*None to report*

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

*None to report*

13. Provide details of any securities issued and options or warrants granted.

*None to report*

14. Provide details of any loans to or by Related Persons.

*None to report*

15. Provide details of any changes in directors, officers or committee members.

*None to report*

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

---

**FORM 7 – MONTHLY PROGRESS REPORT**

None to report


### Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were/is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 6, 2021.

Anne Tew  
Name of Director or Senior Officer

  
Signature

Corporate Secretary  
Official Capacity

<b>Issuer Details</b> Name of Issuer  Sativa Wellness Group Inc.	For Month End June 2021	Date of Report 06/30/21
Issuer Address Suite 409 – 221 503-905 Pender St. W. Esplanade,		
City/Province/Postal Code  Vancouver/BC/V7M 3J3	Issuer Fax No. ( )	Issuer Telephone No. ( )
Contact Name  Anne Tew	Contact Position Corporate Secretary	Contact Telephone No.  +44 (0) 13 7348 2482
Contact Email Address anne@sativawellnessgroup.com	Web Site Address www.sativawellnessgroup.com	

### FORM 7 – MONTHLY PROGRESS REPORT

October 2020  
Page 4